文献速递肝病

HNF4α-CDKL3轴通过非经典磷酸化靶向FoxO1限制MASLD进展

HNF4α-CDKL3 axis restricts MASLD progression by targeting FoxO1 via noncanonical phosphorylation.
PubMed 文献 · Hepatology · 2024-11-13

研究鉴定细胞周期蛋白依赖性激酶样3(CDKL3)为对抗MASLD进展的关键保护因子;肝特异性Cdkl3敲除小鼠出现严重MASLD相关肝炎、纤维化和糖尿病。机制上CDKL3直接磷酸化FoxO1非经典位点,促进其泛素化降解,减少糖原和脂质积累;肝CDKL3受HNF4α直接调控,MASLD时HNF4α受抑导致CDKL3表达下降,形成HNF4α-CDKL3-FoxO1反馈环路。

要点

  • CDKL3是限制MASLD进展的关键保护因子,肝特异性敲除导致严重肝炎、纤维化和糖尿病。
  • CDKL3直接磷酸化FoxO1非经典位点,促进其泛素化降解,减轻糖原和脂质积累。
  • 肝CDKL3是HNF4α直接靶基因,MASLD时HNF4α受抑致CDKL3表达下降。

核心结论

  • 研究揭示了HNF4α-CDKL3轴对FoxO1的非经典调控路径,CDKL3作为对抗MASLD的保护因子,并可能作为FoxO1抑制剂治疗MASLD的预后指标。

研究设计与样本

  • 基础研究:使用肝特异性Cdkl3敲除小鼠模型,结合分子机制实验探讨CDKL3对MASLD进展的调控作用。

主要发现

  • 肝特异性Cdkl3敲除小鼠出现严重MASLD相关肝脏炎症、纤维化和糖尿病。
  • CDKL3直接磷酸化FoxO1非经典位点,通过泛素化依赖途径降解FoxO1,显著减轻糖原和脂质积累,基本阻止向更高MASLD阶段进展。
  • 肝CDKL3是HNF4α直接靶基因;MASLD时HNF4α受抑导致CDKL3表达下降,形成HNF4α与FoxO1经CDKL3介导的反馈环路。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a worldwide disease with a broad spectrum of symptoms. Though mild in early stages, further development of MASLD causes steatohepatitis, cirrhosis, liver cancers, and accompanied diabetes. Discovery of the critical regulators in MASLD progression hold great values in both basic and translational medicine. APPROACH AND RESULTS: Herein, we identified cyclin-dependent kinase-like 3 (CDKL3) as a primary guardian against MASLD progression. Mice with liver-specific Cdkl3 ablation developed severe MASLD-related hepatic inflammation, fibrosis, and diabetes. Mechanism-wise, CDKL3 directly phosphorylates forkhead box O (FoxO)1 on an unconventional site for the ubiquitination-dependent degradation of FoxO1, thereby remarkably alleviating glycogen and lipid accumulation and essentially preventing the onset of higher MASLD stages. Moreover, hepatic CDKL3 is a direct target gene of Hepatocyte nuclear factor 4α (HNF4α). HNF4α is inhibited during MASLD, which leads to diminished CDKL3 expression. The CDKL3-mediated cross talk of HNF4α and FoxO1 hence forms a feedback loop in MASLD progression. CONCLUSIONS: We unearthed an alternative but critical regulatory path of FoxO1 by the HNF4α-CDKL3 axis. CDKL3 serves as a guardian against MASLD and also may function as a prognosis indicator of FoxO1 inhibitor in MASLD treatment.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Pang Z, Zhang H, Zheng S, et al. HNF4α-CDKL3 axis restricts MASLD progression by targeting FoxO1 via noncanonical phosphorylation. Hepatology. 2024. PMID: 39658857. doi:10.1097/HEP.0000000000001147

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。